How will you sequence Dato-DXd among available therapies for HR positive, HER2-0 metastatic breast cancer?

While the approval of Dato-DXd for advanced HR+ HER2- breast cancer offers another TROP2 ADC with an improvement in clinical outcomes, there remain several unanswered questions and uncertainty about how to best utilize and sequence the ADCs for metastatic breast cancer. For patients with HR+ HER2 lo...

I consider Dato-DXd in the third-line setting after endocrine therapy and CDK4/6 inhibitors. In TROPION-Breast01, it significantly improved PFS (6.9 vs 4.9 months; HR 0.63) over chemotherapy. It is particularly appealing for patients with visceral disease, rapid progression, or those who are not ide...

It is wonderful to have another ADC for our patients with advanced breast cancer. Dato-Dxd does not require expression of a biomarker for eligibility, so it is a great option for patients with HER2 0 disease. It is difficult to know how to sequence Dato-Dxd (an anti-TROP2 ADC with the deruxtecan pay...